中国减肥药市场增加新跨国巨头玩家,辉瑞也要加入“价格战”?

第一财经
Feb 24

继诺和诺德、礼来之后,中国的减肥药市场要添加新的跨国巨头玩家了。  2月24日,先为达生物宣布与辉瑞中国达成商业化战略合作协议。  根据协议,辉瑞将获得先为达生物新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液(埃诺格鲁肽)在中国大陆的独家商业化权益;同时先为达生物为许可产品的药品上市许可持有人,负责许可产品的研发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10